Martin Bonde

Board member Martin Bonde is an entrepreneur-in-residence at BiOrigin (a Novo Seeds company). He holds a Ph.D. in Chemical Engineering from the Technical University of Denmark as well as a Graduate Diploma in Business Administration from Copenhagen Business School. Martin started his career in Dako AS, followed by Ostemeter Biotech AS (CEO), Torsana Biosensor A/S (founder and CEO), Celtor Biosystems Inc (EVP), Combio A/S (CEO), Natimmune A/S (CEO), Aros Pharma ApS (founder and CEO), Epitherapeutics Aps (CEO) and most recently Vaccibody AS (CEO). His experience includes fundraising, a significant number of transactions within business development, trade sales, mergers & acquisitions as well as management of research and development. He has board experience from Orphazyme A/S (Nasdaq-OMX: OPRHA), BioInnovation Institute (Board under establishment in the Novo-Nordisk Foundation), DANSK BIOTEK (Chairman 2012-2018), Aros Pharma ApS, and MycoteQ ApS.